Apellis Pharmaceuticals, Inc.
NASDAQ:APLS
29.73 (USD) • At close January 16, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Apellis Pharmaceuticals, Inc. |
Symbool | APLS |
Munteenheid | USD |
Prijs | 29.73 |
Beurswaarde | 3,698,203,890 |
Dividendpercentage | 0% |
52-weken bereik | 24.34 - 71.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Cedric Francois M.D., Ph.D. |
Website | https://www.apellis.com |
An error occurred while fetching data.
Over Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA)
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)